SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT

被引：0
|
作者：
Van Cutsem, E. [1 ]
Berry, S. [2 ]
Michael, M. [3 ]
Kretzschmar, A. [4 ]
Rivera, F. [5 ]
DiBartolomeo, M. [6 ]
Mazier, M. [7 ]
Andre, N.
Cunningham, D. [8 ]
机构：
[1] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium
[2] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic, Australia
[4] Charite Campus Buch, Berlin, Germany
[5] Hosp M Valdecilla, Santander, Spain
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] PARAXEL Int, Biostat & Programming, Paris, France
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [21] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [22] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    [J]. ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [23] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [24] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [25] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [26] Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
    Cassidy, J.
    Cunningham, D.
    Berry, S. R.
    Rivera, F.
    Clarke, S. J.
    Kretzschmar, A.
    Diaz-Rubio, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
    Sledge, G.
    Miller, K.
    Moisa, C.
    Gradishar, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date
    Zhang, Guoliang
    Zhou, Xile
    Lin, Caizhao
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (01): : 1434 - 1445
  • [29] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [30] The study of efficacy and safety of chemotherapy plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer.
    Takano, Nao
    Nakayama, Goro
    Kodera, Yasuhiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345